The Ischemic Cardiomyopathy drugs in development market research report provides comprehensive information on the therapeutics under development for Ischemic Cardiomyopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Ischemic Cardiomyopathy. Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Ischemic Cardiomyopathy and features dormant and discontinued products.

GlobalData tracks ten drugs in development for Ischemic Cardiomyopathy by ten companies/universities/institutes. The top development phase for Ischemic Cardiomyopathy is phase ii with four drugs in that stage. The Ischemic Cardiomyopathy pipeline has eight drugs in development by companies and two by universities/ institutes. Some of the companies in the Ischemic Cardiomyopathy pipeline products market are: Hemostemix, Rohto Pharmaceutical and Osaka University Hospital.

The key targets in the Ischemic Cardiomyopathy pipeline products market include High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1), Vascular Endothelial Growth Factor Receptor 1 (Fms Like Tyrosine Kinase 1 or Tyrosine Protein Kinase Receptor FLT or Tyrosine Protein Kinase FRT or Vascular Permeability Factor Receptor or VEGFR1 or FLT1 or EC, and Neuropilin 1 (Vascular Endothelial Cell Growth Factor 165 Receptor or CD304 or NRP1).

The key mechanisms of action in the Ischemic Cardiomyopathy pipeline product include Prostacyclin Receptor (Prostaglandin I2 Receptor or Prostanoid IP Receptor or PTGIR) Agonist with one drug in Phase II. The Ischemic Cardiomyopathy pipeline products include six routes of administration with the top ROA being Intracardiac and five key molecule types in the Ischemic Cardiomyopathy pipeline products market including Cell Therapy, and Recombinant Protein.

Ischemic Cardiomyopathy overview

Ischemic cardiomyopathy is a type of cardiomyopathy caused by a narrowing of the coronary arteries that supply blood to the heart. Patients with ischemic cardiomyopathy often have a history of acute myocardial infarction (MI), but it may occur in patients with coronary artery disease but no past history of acute MI. This cardiomyopathy is one of the leading causes of sudden cardiac death. The adjective ischemic means it is characteristic of, or accompanied by, local anemia due to mechanical obstruction of the blood supply.

For a complete picture of Ischemic Cardiomyopathy’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.